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Abstract
Objective—Polymorphisms within the ICAM1 structural gene have been shown to influence
circulating levels of soluble intercellular adhesion molecule -1 (sICAM-1) but their relation to
atherosclerosis has not been clearly established. We sought to determine whether ICAM1 SNPs
are associated with circulating sICAM-1 concentration, coronary artery calcium (CAC), and
common and internal carotid intima medial thickness (IMT).
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Methods and Results—3,550 black and white Coronary Artery Risk Development in Young
Adults (CARDIA) Study subjects who participated in the year 15 and/or 20 examinations and
were part of the Young Adult Longitudinal Study of Antioxidants (YALTA) ancillary study were
included in this analysis. In whites, rs5498 was significantly associated with sICAM-1 (p < 0.001)
and each G-allele of rs5498 was associated with 5% higher sICAM-1 concentration. In blacks,
each C-allele of rs5490 was associated with 6 % higher sICAM-1 level; this SNP was in strong
linkage disequilibrium with rs5491, a functional variant. Subclinical measurements of
atherosclerosis in either year 15 or year 20 were not significantly related to ICAM1 SNPs.
Conclusions—In CARDIA, ICAM1 DNA segment variants were associated with sICAM-1
protein level including the novel finding that levels differ by the functional variant rs5491.
However, ICAM1 SNPs were not strongly related to either IMT or CAC. Our findings in
CARDIA suggest that ICAM1 variants are not major early contributors to subclinical
atherosclerosis.
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Introduction
Atherogenesis is a chronic inflammatory process. Steps in the inflammatory process include
accumulation of lipids, recruitment of leukocytes and smooth muscle cells into vessel walls,
and accumulation of extracellular matrix. Intercellular adhesion molecule-1 (ICAM-1) is
integral in these cellular processes as interactions between ICAM-1 and activated receptors
on the leukocytes result in firm adhesion and transmigration of leukocytes into the basement
membrane of the vasculature. Therefore, ICAM-1 may be an important contributor to the
development and progression of atherosclerotic disease.
Nakashima et al. showed upregulation of ICAM1 at atherosclerosis-prone sites, and animal
studies have shown a reduction in atherosclerosis in mice deficient in ICAM-11-4.
Circulating soluble ICAM-1 (sICAM-1) is thought to be the result of cleavage of membrane-
bound ICAM-1 and its concentration in serum/plasma has an estimated heritability ranging
from 0.34-0.505, 6. Several human studies have found high levels of inflammatory-related
markers in patients with cardiovascular disease7-10. The ARIC study reported the odds of
coronary heart disease and carotid artery atherosclerosis were 5.5 and 2.6 times higher
respectively, for those with levels of sICAM-1 in the highest quartile compared with those in
the lowest quartile10. The Women’s Health Study reported a relative risk of 2.6 for
cardiovascular events for women in the highest quartile of sICAM-1 levels compared to
lowest11.
Results from three genome-wide linkage scans of sICAM-1 showed significant linkage on
chromosome 19 near the ICAM1 structural gene6, 12, 13. Polymorphisms within the ICAM1
structural gene have been shown to influence circulating levels of sICAM-1 but the relation
of these polymorphisms and atherosclerosis remains inconclusive14, 15. Furthermore, the
relationship of ICAM1 SNPs on sICAM-1 levels and atherosclerosis in younger populations
is unknown. Therefore, we sought to determine whether variations within the ICAM1 gene
are associated circulating sICAM-1 concentrations and subclinical atherosclerosis in a
cohort of young adults.
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This cross-sectional study was part of the Young Adult Longitudinal Study of Antioxidants
(YALTA), an ancillary study to the Coronary Artery Risk Development in Young Adults
(CARDIA) study, a cohort study, which tracks the evolution of cardiovascular disease risk
factors in human subjects beginning at ages 18-30 in 1985-86. CARDIA recruited a
population based sample of 5,115 black and white men and women in Birmingham, AL,
Chicago, IL, Minneapolis, MN, and Oakland, CA with participants reexamined at years 2, 5,
7, 10, 15, and 20. Overall retention rates for follow-up examinations among surviving
participants were: 91% at year 2, 86% at year 5, 81% at year 7, 79% at year 10, 74% at year
15, and 71% at year 20. Further details of the study have been described elsewhere16. This
analysis was based on subjects who participated in the year 15 examination that occurred
between May 2000 and June 2001 and who had available fasting plasma samples and
consented to the use of their DNA. Analysis involving subclinical atherosclerosis measures
required participation in the year 20 examination as IMT was only measured at the year 20
exam.
Measurements
Demographic, and lifestyle information were collected via questionnaire, and measurements
were taken of height and weight to calculate body mass index (BMI, kg/m2). Resting
systolic and diastolic blood pressure was measured using the averages of the second and
third random zero sphygmomanometer measurements.
Overnight fasting blood samples were collected and processed within 90 minutes of blood
collection and stored at -70°C. Soluble ICAM-1 concentrations were measured in serum
(R&D Systems; Cat No DY720). The limit of sensitivity of the ICAM-1 assay was 15 pg/
mL and the coefficient of variation was 9.4%. The correlation of 287 pairs of blinded quality
control samples was 0.884. Plasma total cholesterol, HDL-cholesterol, and triglycerides
were measured enzymatically at the Northwest Lipid Research Laboratory at the University
of Washington, Seattle, WA. High-density lipoprotein cholesterol (HDL-C) was determined
after precipitation of low-density lipoprotein (LDL)-containing lipoproteins with dextran
sulfate/magnesium chloride. LDL-cholesterol (LDL-C) was calculated using the Friedewald
equation; the few individuals with triglycerides over 4.52 mmol/liter (400 mg/dL) were
excluded from this calculation. The test-retest correlation, in 448 blind duplicate samples,
was 0.98-0.99 for total cholesterol, HDL-C, LDL-C, and triglycerides.
Coronary artery calcium (CAC) was measured in years 15 and 20 in Oakland, CA and
Chicago, IL by electron beam CT (Imatron, Inc.) and in Birmingham, AL and Minneapolis,
MN by multidetector CT (General Electric Lightspeed in Birmingham and Siemens S4+
Volume Zoom in Minneapolis). Pregnant women and those subjects who exceeded the
weight restriction for the scanner were ineligible. The CT scanning protocol included a
hydroxyl-apatite phantom to monitor image brightness and noise, and adjustment of scanner
differences in brightness levels during reading and to allow comparability of scans among
sites. A radiologist identified the courses of the coronary arteries using specially developed
image processing software programmed to define a calcified focus as 4 adjacent pixels
comprising an area of at least 1.87 mm2. Agatston scores calculated for each artery (left
main, left anterior descending, left circumflex, and right coronary artery) were summed
across all arteries to obtain the total calcium score used in all analyses. Scans were done in
duplicate; scan pairs were adjudicated side-by-side by a radiologist and in those judged
falsely positive the Agatston score was reset to zero.
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Carotid ultrasound was performed at the year 20 CARDIA using a standard protocol. The
maximum intima-media thicknesses (IMT) of the common carotid artery and the bulb/
internal carotid artery were defined as the mean of the maximal IMT of the near and far wall
on both the left and right sides.
Haplotype tagging SNPs in the ICAM1 structural gene were selected based on a R2 cut-off
of 0.8 and a minor allele frequency greater than 0.05. The hapolotype tagging SNPs were
selected separately for African Americans and European Americans. Genotyping was
carried out with a combination of mass spectrometry based on multiplex methods
(Sequenom, San Diego, CA) and TaqMan (Applied Biosystems, Foster City, CA) assays.
Those SNPs failing design or quality control in the multiplex methods were moved to the
TaqMan assay. Primers and probes for the genotyping assays are available from the authors
upon request.
Statistical Analysis
Hardy Weinberg equilibrium (HWE) was assessed using the log likelihood ratio test
stratified by race for all SNPs. Haploview was used to determine linkage disequilibrium.
Associations between genotype and sICAM-1 were assessed with linear regression. In
CARDIA, roughly 80% of the participants at both exams had a CAC score of zero and the
remaining non-zero scores were highly skewed. Therefore, we modeled CAC in two ways,
as a continuous trait, log (Agatston Score +1), and as a dichotomous trait (presence or
absence of CAC). All associations were stratified by race/ethnicity to reduce confounding
due to population stratification and to evaluate heterogeneity in the associations. We used
logistic regression to assess the association between genotype and the presence of CAC.
Generalized linear models (GENMOD) were used to determine the association between
genotype and continuous CAC and IMT measures. SNP genotypes were analyzed for
predicting association under an additive model relating the number of minor alleles (0, 1, 2)
to phenotype. Only SNPs with > 1% allele frequency in each racial group were included in
the analysis. To correct for multiple comparisons, we used a Bonferroni correction based on
the total number of race-SNP tests, giving us a threshold of p < 0.002 (0.05/22).
The associations of ICAM1 SNPs, sICAM-1, CAC, and IMT were assessed with and
without covariates. Covariates included age, sex, center, smoking status, alcohol
consumption, HDL cholesterol, LDL cholesterol, triglycerides, and fasting insulin, and
glucose measured at exam 15. In blacks only, an ancestry estimate was included as a
covariate. We report the most parsimonious model that includes only genotype as the
addition of covariates did not materially change any of the associations.
Results
Study characteristics by race are listed in Table 1. Blacks were slightly younger and more
likely female, had significantly thicker IMT at both sites (internal, p = 0.003 and common, p
< 0.001) and higher levels of sICAM-1 (p < 0.0001). Conversely, whites had significantly
more coronary calcium on average in year 15 (p < 0.001) and year 20 (p < 0.002). ICAM1
SNP allele frequencies by race are listed in Online Table 1 with descriptions of the SNPs
including amino acid substitution and location. With two exceptions in blacks only,
rs281431 and rs281434, all ICAM1 SNPs were in HWE (p > 0.05). For SNP rs281434 there
were fewer heterozygotes than expected (p = 0.005) and for rs281431 there were more
heterozygotes than expected (p = 0.04) (Online Table 2). Online Figures 1 and 2 illustrate
the linkage disequilibrium plots generated by Haploview for each race. Online Figures 3 & 4
illustrates SNP associations across the ICAM1 gene for each racial group.
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Geometric means of sICAM-1 concentration by genotype are listed in Table 2 for all
ICAM1 SNPs. In whites, rs5498 and rs3093030 were significantly associated with sICAM-1
(p < 0.001). SNP rs5498 encodes a non-synonymous substitution in exon 6, whereas
rs3093030 is located in the 5’ region. These two SNPs are in strong LD in whites, r2 = 0.93.
To further investigate this association we performed an analysis on the rs3093030 and
sICAM-1 relationship conditioning on rs5498 genotype (i.e. including rs5498 in the model
as a covariate). The association remained significant, at the p = 0.05 level, for rs5498 (p =
0.01) but not for rs3093030 (p = 0.15). Each G-allele of rs5498 was associated with 5%
higher sICAM-1 level per allele. Six other SNPs were associated at the p = 0.05 level and
are in LD with rs5498 (r2 ranges 0.04-0.30); rs5030390 (p = 0.04), rs281430 (p = 0.03),
rs281431 (p = 0.02), rs281434 (p = 0.02), rs281437 (p = 0.03), and rs3093032 (p = 0.03).
However, after conditioning on rs5498, none of those six SNPs were related to sICAM-1
level (p > 0.19) while rs5498 remained significant (p < 0.0001). In blacks, rs5498 was not
associated with sICAM-1 level (p = 0.72).
In blacks, rs5490 was significantly associated with sICAM-1 level (p < 0.0008). Each C-
allele was associated with 6 % higher sICAM-1 level. ICAM1 SNPs rs281430 (p = 0.01),
rs281431 (p = 0.04), rs281432 (p = 0.04), and rs281437 (p = 0.01) were all modestly
associated with sICAM-1 level and in LD with rs5490 (r2 ranges 0.01-0.15). After
conditioning on rs5490, only rs281437 remained modestly associated with sICAM-1 (p =
0.04) while the other four SNPs were unrelated (p > 0.23) and rs5490 remained a strong
predictor (p = 0.0004). We did not assess these relationships in whites as this SNP is rare,
frequency < 1%.
For the year 15 CAC measurement, there were no ICAM1 SNPs associated with CAC in
either racial group (Online Tables 3 & 4). For year 20, there were no ICAM1 SNPs
significantly (p > 0.002) related to either CAC or IMT. However, several SNP were
associated with subclinical disease at the p = 0.05 level. In blacks, SNPs rs3093030,
rs281434, rs5498, rs5030362, and rs5490 were all associated with common carotid IMT (p
range 0.02-0.05). In addition to common carotid IMT, rs5490 was also associated with
presence of CAC (OR = 1.4 per C-allele, p = 0.02) but not continuous CAC (p = 0.23) in
year 20. In whites, only rs281437 was marginally related to internal IMT (p = 0.04)
Discussion
This study sought to determine the relationship of variants within the ICAM1 structural
gene, circulating sICAM-1, and subclinical atherosclerosis in a cohort of young adults. This
study shows that ICAM1 SNPs are associated with sICAM-1 levels in a relatively young
healthy population, replicating the results from cohorts of older subjects and demonstrating
genetic influences of levels of this risk factor at the earliest stages of atherosclerosis.
Specifically, each minor allele of rs5498 was associated with a 5% higher sICAM-1 level in
whites and the minor allele of rs5490 was associated with a 6% higher sICAM-1 levels in
blacks. No strong associations of these variants with IMT or CAC were observed.
ICAM1 SNP rs5498 is a functional mutation located at the C-terminus encoding a glutamic
acid – lysine substitution in exon six and as stated above is in strong LD with intronic SNP
rs3093030. Consistent with our results in whites, this SNP has been previously associated
with sICAM-1 level in a German pediatric asthma population17 and whites in the Multi-
ethnic Study of Atherosclerosis (MESA) with no association observed in blacks14. This
result corroborates findings from a genome wide association study in whites of sICAM-1 in
the Women’s Genome Health Study that identified three ICAM1 SNPs, rs1799969, rs5498,
and rs281437, that were significantly related with sICAM-1 at a genome-wide significance
level18. Further replication of this association was reported ~10,000 individuals of European
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Ancestry in the Cohorts for Heart and Aging Research in Genome Epidemiology
(CHARGE) Consortium13.
SNP rs5498 is located 3 base pairs upstream of a splice donor site that produces an
alternatively spliced form of ICAM-1 that lacks a transmembrane and intracellular domain
(ICAM-1-S). Using human peripheral mononuclear cells and Epstein-Barr virus transformed
peripheral mononuclear cells, Iwao et al demonstrated that carriers of the G-allele may have
more difficulty splicing ICAM-1-S compared to the A-allele resulting in GG cells having
less mRNA for ICAM-1-S19. Therefore, one hypothesis given these results is that due to
disruption of the splice site, carriers of the G-allele produce less ICAM-1-S and more
ICAM-1-L that contains both transmembrane and cellular domains. Given that sICAM-1 is
thought to be produced by cleavage of membrane bound ICAM-120, individuals who
produce more ICAM-1-L would likely have higher levels of sICAM-1. Differing linkage
disequilibrium patterns between ethnic groups for rs5498 and splice site mutations may
account for the lack of replication for rs5498 on sICAM-1 levels in blacks. However, in
contrast to previous studies, including the CARDIA results reported here, Iwao et al reported
that total sICAM-1 was similar for both homozygote samples but ~50% lower in the
heterozygote cells19. Interactions between ICAM1 SNPs and ELISA ICAM-1 assays are
well-documented in the literature21, 22. However, it is unknown as to whether assay affinity
differences by genotype account for this discrepancy.
SNP rs5490 is located in the 5’UTR and was associated with sICAM-1 in blacks. Based on
data from HapMap African samples this SNP is in strong LD with rs5491 (r2 = 0.78), a
functional variant, with the rs5490 C-allele and the rs5491 T-allele commonly residing on
the same haplotype. It has been hypothesized that the T-allele of rs5491 confers protection
against malarial infection23; hence the allele is common in African populations with a
frequency of 0.25 in Yoruban and monomorphic in Europeans based on HapMap data. The
T-allele of rs5491 encodes a lysine to methionine substitution in exon 2 in the N-terminal
domain of ICAM-1 and results in a protein that is unable to bind to fibrinogen and has a
decreased affinity for T-cells at lower ICAM-1 concentrations compared to wild type
ICAM-123. A commonly used R&D Systems sICAM-1 assay is unable to recognize
sICAM-1rs5491T making the assessment of rs5491 on sICAM-1 concentrations impossible in
studies using the problematic assay21. In CARDIA, an alternative assay was used that is not
affected by this variant and for the first time we are able to show that sICAM-1 protein
concentrations differ by rs5491 genotype. However, given the lack of knowledge regarding
the functionality of rs5490 and the lack of genotype data for rs5491 in CARDIA, we are
unable to determine if the observed association with sICAM-1 is caused by rs5490, rs5491,
or another functional variant in LD.
ICAM1 SNP rs281437 is modestly associated with sICAM-1 in blacks after conditioning on
rs5490. This SNP is located in the 3’ UTR and was identified in a recent genome wide
association study of sICAM-1 in whites18. Other relationships for rs281437 are absent from
the literature, because this SNP has not been genotyped in other populations.
Several reasons could explain the heterogeneity of associations by race seen in previous
studies and corroborated by this investigation. Possible mechanisms causing the racial
heterogeneity may include genotype frequency differences affecting the power to detect
associations, differing LD patterns between racial groups, and evidence of selection pressure
at this locus where malaria is endemic23. As with any candidate gene study, LD patterns
make it difficult to positively identify the causal variant.
In CARDIA, ICAM1 SNPs were not significantly associated with subclinical atherosclerosis
but the power to detect an association was limited in this cohort; especially considering that
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genetic association results of most complex biological traits has shown us that the effect size
of a single variant is small. The best case in terms of power for our data is for the SNP with
the highest minor allele frequency in each racial group and the presence of CAC at year 20.
For this case, we have 80% power to detect an OR of 1.5 in blacks for rs281437 and 1.4 in
whites for rs5498. Power is reduced for all other SNP-subclinical measurement
combinations. Considering these same two SNP-race combinations, we have 80% power to
detect an OR of 1.8 in blacks and 1.6 in whites for CAC at year 15 and differences in IMT
ranging from 0.02-0.04 mm. Thus, identification of SNPs with minor effects is challenging
in this cohort. However, despite our limited power, several SNPs were modestly associated
with subclinical disease including rs3093030, rs281434, rs5498, rs5030362, and rs5490 in
blacks and rs281437 in whites. Several previous studies have found an association with
ICAM1 SNPs and cardiovascular disease, albeit inconsistently. In a German case control
study, rs5498 was associated with an OR = 2.2 for coronary heart disease24, in the Study of
Inherited Risk of Coronary Atherosclerosis (SIRCA) this SNP was associated with CAC in
men independently of sICAM-1 level25, and was associated with a higher risk of restenosis
after coronary stenting in Chinese26. The rs5498 SNP was also associated with peripheral
arterial occlusive disease in an Italian population27. Conversely, ICAM1 variants were not
associated with ischemic heart disease28, coronary heart disease29, myocardial
infarction29, 30, or incident cardiovascular disease31. Furthermore, ICAM1 variants were not
associated with CAC in the MESA Study14.
This investigation has several strengths. CARDIA is a large population-based study with
ample sample size in two racial groups to investigate the relationship between ICAM1 SNPs
and sICAM-1. Furthermore, CARDIA is unique in that the subjects were recruited at a
relatively young age allowing for the evaluation of risk factors at the earliest stages of
atherosclerosis.
Conclusion
In CARDIA, ICAM1 variants associated with sICAM-1 protein levels but were not strongly
related to either IMT or CAC. Our findings in CARDIA suggest that ICAM1 variants are
not major early contributors to subclinical atherosclerosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics by race (mean ± SD, percentage, or count)
Variables Black (n = 1652) White (n = 1898) p-value
Year 15 Age, years 40 ± 3.8 41 ± 3.4 < 0.001
Male, % 681 (41) 893 (47) 0.005
Internal Carotid IMT, mm 0.95 ± 0.22 0.92 ± 0.22 0.003
 range, mm 0.44-2.64 0.45-3.0
Common Carotid IMT, mm 0.83 ± 0.13 0.77 ± 0.11 < 0.001
 range, mm 0.53-1.84 0.51-1.35
sICAM-1, ng/mL 166 ± 50 146 ± 38 < 0.001
Year 15 Measurements
CAC Present (%) 7.5 11.3 < 0.001
Range, Agatston Score 0-2236 0-3521
Agatston Score Categories, n (%)
 ▪ 0 1263 (92) 1473 (89) 0.004
 ▪ 1-100 85 (6) 158 (10)
 ▪ 101-299 11 (1) 22 (1)
 ▪ 300+ 7 (1) 7 (< 1)
Year 20 Measurements
CAC Present (%) 16.1 20.5 0.004
Range, Agatston Score 0-6057 0-5350
Agatston Score Categories, n (%)
 ▪ 0 1112 (84) 1323 (80) 0.02
 ▪ 1-100 162 (12) 259 (16)
 ▪ 101-299 37 (3) 47 (3)
 ▪ 300+ 14 (1) 29 (2)
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Table 2
Geometric means for ICAM1 SNP associations with sICAM-1 by race
ICAM1 SNP Geometric mean sICAM-1 levels*, ng/mL (n) p-value
blacks
 rs3093030 (CC,CT,TT) 161 (1186) 161 (304) 158 (25) 0.64
 rs5030390 (GG,GA,AA) 161 (1449) 168 (38) n.a. 0.42
 rs281430 (GG,GA,AA) 165 (595) 160 (717) 154 (212) 0.01
 rs281431 (CC,CT,TT) 166 (543) 161 (669) 158 (161) 0.04
 rs281432 (GG,GC,CC) 164 (724) 158 (643) 157 (152) 0.04
 rs281433 (AA,AC,CC) 160 (1298) 166 (217) 201 (10) 0.06
 rs281434 (GG,GA,AA) 161 (713) 161 (602) 161 (177) 0.95
 rs5498 (AA,AG,GG) 160 (963) 163 (465) 163 (54) 0.72
 rs281437 (CC,CT,TT) 158 (648) 161 (673) 168 (196) 0.01
 rs3093032 (CC,CT,TT) 161 (1447) 156 (81) 147 (4) 0.36
 rs5030362 (AA,AC,CC) 174 (15) 167 (252) 160 (1248) 0.10
 rs5490 (AA,AC,CC) 157 (937) 168 (516) 176 (79) 0.0007
whites
 rs3093030 (CC,CT,TT) 137 (548) 145 (843) 150 (356) < 0.0001
 rs3093035 (GG,GA,AA) 143 (1562) 144 (134) n.a. 0.82
 rs5030390 (GG,GA,AA) 144 (1499) 140 (244) 127 (9) 0.04
 rs281430 (GG,GA,AA) 140 (261) 142 (901) 146 (650) 0.03
 rs281431 (CC,CT,TT) 140 (248) 142 (863) 146 (624) 0.02
 rs281432 (GG,GC,CC) 145 (338) 142 (902) 144 (543) 0.79
 rs281434 (GG,GA,AA) 145 (1261) 139 (498) 142 (51) 0.02
 rs5498 (AA,AG,GG) 137 (538) 145 (831) 151 (350) < 0.0001
 rs281437 (CC,CT,TT) 145 (937) 142 (757) 139 (128) 0.03
 rs3093032 (CC,CT,TT) 144 (1354) 140 (428) 136 (40) 0.03
*
Only SNPs with a frequency of >1% were included
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